Revance Therapeutics Inc (NASDAQ: RVNC) stock closed at $8.43 on 12/21/23 after a major increase of 11.2%. However, trading volume in this advance was below average at 67% of normal. The stock has risen 6.4% during the last week but has been extremely weak relative to the market over the last nine months.
Current PriceTarget Research Rating
RVNC is expected to be Value Creation neutral reflecting capital returns that are forecasted to be in line with the cost of capital.
Revance Therapeutics has a current Value Trend Rating of F (Lowest Rating). This rating combines highly consistent signals from two proprietary PTR measures of a stock’s attractiveness. Revance Therapeutics has a very low Appreciation Score of 0 and a very low Power Rating of 0, and the Lowest Value Trend Rating results.
Rating Review
In light of this very positive price change we are reviewing our current Overall Rating of F. This review will be completed in the next several days.
Be the first to comment